Abstract
Aim: To characterize the biochemical features of the newest member of cyclophilin family of peptidyl-prolyl cis/trans-isomerases (PPIases), cyclophilin J (CYPJ). Materials and Methods: PPIase assays were performed on purified hCYPJ and its mutated variants. The substrate specificity, half-maximal inhibitory concentration (IC50) of cyclosporin A (CsA) inhibition and circular dichroism (CD) spectrum of CYPJ were measured. Mercury pathway profiling luciferase assays were also performed. Results: The catalytic number/Michaelis constant (kcat/KM) value of CYPJ was 9.5×104 s−1M−1. CYPJ additionally catalyzed norleucine-proline, isoleucine-proline and glutamine-proline peptides compared to CYPA and Escherichia coli PPIases. CYPJ was inhibited by CsA in a dose-dependent manner with IC50 of 12.1±0.9 μM. The CD spectrum of CYPJ was similar to CYPA. CYPJ significantly up-regulated the transcription of E-box, E2F, retinoblastoma (Rb), p53, activator protein 1 (AP1), NF-κB and phospho-cAMP response element (CRE) cis-response element in 293T cells. Conclusion: CYPJ structurally resembles CYPA. It is sensitive to inhibition by CsA and plays a role in regulating cell growth, proliferation, and apoptosis.
Cyclophilins (CYPs) are a large family of peptidyl-prolyl cis/trans-isomerases (PPIases, EC 5.2.1.8) that can selectively bind to cyclosporin A (CsA). As an immunosuppressive drug, CsA interrupts the T-cell signalling pathway by inducing false folding of T-cell membrane protein after forming a CsA–cyclophilin complex (1). CYPs are involved in a large variety of biological events across cells, including immunosuppression, signal transduction, the allosteric effect and assembly of proteins (2-4), mitochondria-related apoptosis (5), RNA splicing (6, 7), mitosis (8, 9), tumourigenesis (10, 11) and HIV infection (12-14).
CYPs are highly conserved proteins that exist extensively and have been isolated from a large variety of organisms including Bacillus, Escherichia coli, yeast, plants and eukaryotes (15, 16). To date, 17 different types of CYPs have been identified in the human genome, with molecular weights between 8 and 150 kDa. The coding sequence of the latest member of human cyclophilin family, CYPJ, was first reported as one of the two transcript variants of human peptidylprolyl isomerase-like 3 (PPIL3B) gene in 2001 (17). Human CYPJ protein was purified and crystalized by Huang et al. in 2004, and showed 72% sequence identity to CYP10 in Caenorhabditis elegans and 50% to human CYPA (18). hCYPJ was reported to bind CsA with similar active-site structure but with somewhat different binding details from those for hCYPA–CsA complex (18).
CYPJ contains the PPI consensus sequence [F/Y]–X(2)–[S/T/C/N/L/V]–X–F–H–[R/H]–[L/I/V/M/N]–[L/I/V/M]–X(2)–F–[L/I/V/M]–X–Q–[A/G]–G (19), suggesting its role as a PPIase. However, the biochemical properties of CYPJ as a PPIase remain to be explored. Herein, we studied the enzymatic kinetics of CYPJ and its interaction with binding partner CsA.
Materials and Methods
Protein expression and purification. Construction of CYPJ expression plasmid and protein expression was performed as previously described (18) except that E. coli Rosetta cells (Novagen, Shanghai, China) were used for protein expression in this study. Purified protein was analyzed by liquid chromatography/mass spectrum (LC/MS) (20), or kept in PPIase buffer (50 mM HEPES, pH 8.0, and 86 mM NaCl) at 4°C until use. Samples were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with coomassie brilliant blue (Sigma-Aldrich, Shanghai, China).
Biochemical assays. PPIase activity assays of CYPJ were performed at 10°C in quartz cuvettes with a path length of 1 cm under vigorous stirring with a U-3000 spectrophotometer (Hitachi, Tokyo, Japan) in 35 mM HEPES buffer at pH 7.8. Enzyme activities of 100 nM CYPJ towards the substrate Suc-A-A-P-F-pNA (Sigma-Aldrich, Shanghai, China) were measured using the protease-free assay according to Janowski et al. (21) in the additional presence of isomerase-specific protease chymotrypsin (0.83 mg/ml final concentration).
CsA inhibition assays were carried out as described above using 105.5 nM CYPJ and the samples were pre-incubated for 60 min on ice with differing amounts of CsA (Sigma-Aldrich, Shanghai, China) in 50% (v/v) ethanol/water.
For the substrate specificity assay, Suc-A-Xaa-P-F-pNA (Xaa represents a serial of amino acid residuals) was used as substrate, and the catalytic constant catalytic constant/Michaelis constant (kcat/KM) values of CYPJ, CYPA, E. coli PPIase a and E. coli PPIase b were tested and calculated.
Circular dichroism (CD) spectroscopy. CD spectroscopic measurements of CYPJ and CYPA were performed on a CD spectrometer (Jasco, Shanghai, China) at 10°C at a wavelength of 200-250 nm. CYPA concentration was 10 μM in 10 mM phosphate buffer, pH 7.5, d=0.1 cm. CYPJ concentration was 10 μM in 50 mM phosphate buffer, pH 8.5, d=0.1 cm. Each curve represented a combined result of five scans. For the thermal stability CD spectroscopic analysis, the CYPJ solution in the cuvette was covered with paraffin oil to prevent evaporation. CYPJ was incubated for 10 min at 25 °C and a 10 °C increment between 40-90°C before the CD spectrum was measured.
Fluorescence spectroscopy. Peptide substrate was mixed with 3.5 μM CYPJ. The fluorescence emission curve of CYPJ was obtained using a FP-777 spectrofluorometer (Jasco, Shanghai, China) by subtracting the fluorescence intensity of respective peptide substrate from that of the whole reaction mixture, and then corrected for the internal standard filtering effect (22).
Luciferase assay. The Mercury™ pathway profiling luciferase system (Clontech, CA, USA) was used for testing the effect of CYPJ on multiple signalling pathways according to manufacturer's instructions. pCMV-CYPJ-myc plasmid was constructed by cloning the coding sequence of human CYPJ into pCMV-myc vector. 293T cells (ATCC, Manassas, USA) (3×104) were inoculated in 24-well plates and cultured for 18-24 h at 37°C in an atmosphere of 5% CO2. Reporter plasmid (100 ng of pAP1-Luc, pCRE-Luc, pNFκB-Luc, pE2F-TA-Luc, pMyc-TA-Luc, pp53-TA-Luc or pRb-TA-Luc), 10 ng inner referencing plasmid pRL-SV40 and 400 ng either pCMV-CYPJ-myc (+ve) or pCMV-myc (−ve) vector were simultaneously transfected with Lipofectin Reagent (Invitrogen, Shanghai, China). Cells were lysed after 5 days' culture, and the luciferase activity was detected using an LB9507 luminometer (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). The luminance intensity was recorded. For each signalling pathway, the fold increase of transcription level was calculated as =M2+M1+/M2−. (where M2: mean luminance from the reporter plasmid; M1: mean luminance from the inner referencing plasmid; +/−: +ve or −ve group.
Statistical analysis. Data are presented as the mean values and standard deviation of the sample. Statistical analysis was performed using the two-tailed Student's t-test. A value of p<0.05 was considered statistically significant.
Results
Expression and purification of recombinant human CYPJ protein. In order to characterize CYPJ biochemically, we expressed and purified recombinant CYPJ from pTXB1 vector in E. coli. After affinity chromatography and gel chromatography purifications, high-purity recombinant CYPJ protein was obtained. SDS-PAGE showed an overexpression of recombinant protein of approximately 44 kDa (Figure 1A) and a single band of purified digested protein of approximately 19 kDa (Figure 1B). The relative molecular weight of the purified protein was 19379.34 Da, as determined by LC/MS (Figure 1C).
PPIase activity of CYPJ. The PPIase enzymatic activity of hCYPJ was determined. In the chymotrypsin-coupled assay with different concentrations of the peptide substrate, the recombinant human CYPJ appeared to follow Michaelis–Menten kinetics. The values of kcat and KM were determined by a double reciprocal Lineweaver–Burke plot of 1/v against 1/[S], yielding a kcat/KM value of 9.5×104s−1M−1 (Figure 2A). Several key amino acids (R44, F49, K120) have previously been reported to be important for the catalytic activity of CYPA protein (23). The corresponding mutants were generated (R44A, R44A&F49A, and K120A) for CYPJ and their residual PPIase activities were assayed and compared to those of the wild-type CYPJ protein. The R44A, R44A&F49A, and K120A CYPJ mutants displayed 57%, 32% and 87% of the wild-type enzyme activity, respectively, that was consistent with the roles of these residues in catalysis (Figure 2B).
To further characterize the PPIase enzyme activity of CYPJ, different Suc-A-Xaa-P-F-pNA were used as substrates in PPIase assay and the kcat/KM values of CYPJ were compared with those of hCYPA, E. coli PPIase a and E. coli PPIase b (Table I). The results show that in addition to the common substrates for CYPA and E. coli PPIases, CYPJ also catalyzes the cis/trans isomerization of norleucine-proline, isoleucine-proline and glutamine-proline peptides.
The inhibitory effect of CsA on PPIase activity of CYPJ was also examined. The results showed that CYPJ was inhibited by CsA in a dose-dependent manner and the IC50 was determined to be 12.1±0.9 μM (Figure 3).
Physicochemical properties of CYPJ. CD spectroscopic analysis showed that recombinant CYPJ comprised of 10.5% α-helix, 51.6% β-sheets and 37.9% coil. The CD spectrum of CYPJ resembled that of CYPA (Figure 4A). During thermal denaturation, the secondary structure of CYPJ remained stable below 40°C. When reaching 50°C, the number of secondary structures significantly decreased in CYPJ with the appearance of many random conformations (Figure 4B). We also tested the CD spectrum of CYPJ with different concentrations of CsA. With increasing CsA concentration, the ratio of α-helix increased, while the number of coils decreased (Figure 4C).
The excitation spectrum of CPYJ revealed 280 nm to be its maximum fluorescence excitation wavelength. With increaseing concentration of peptide substrate, the fluorescence intensity of CYPJ decreased, with redshifted maximum emission wavelength (Figure 4D), indicating an interaction of the protein with substrate. The induction by substrate caused changes in the conformation of tryptophan.
Involvement of CYPJ in signaling pathways. To investigate the involvement of CYPJ in a number of signaling pathways, we performed luciferase assays in 293T cells transfected with a number of different reporter plasmids (Figure 5) together with inner referencing vector pRL-SV40 and CYPJ expression vector pCMV-CYPJ-myc. pCMV-myc empty vector was used instead of pCMV-CYPJ-myc as a negative control. Results showed that compared to the empty vector, the pCMV-myc plasmid expressing CYPJ significantly increased the transcription of luciferase reporter gene with the E-box (p=2.251×10−6), E2F (p=0.00341), Rb (p=1.144×10−4), p53 (p=1.166×10−5), AP1 (p=4.144×10−6), NFκB (p=9.802×10−4) or CRE (p=1.831×10−4) cis-response element in 293T cells (Figure 5), suggesting strong up-regulatory effects of CYPJ in the corresponding signaling pathways.
Discussion
In this study, we expressed and purified the new member of human cyclophilin family, CYPJ, and investigated its biochemical features. We demonstrated that CYPJ is a PPIase that is sensitive to inhibition by CsA.
The predicted that the molecular weight of human CYPJ was 18,154 Da, while LC/MS showed our recombinant CYPJ to be 19,379.34 Da, most likely due to the MASSRVDG and LEGSS residue on the N and C ends of CYPJ after cleavage from the pTXB1-expressed fusion protein. Therefore, discrepancy might exist between the properties of our recombinant protein and its natural counterpart.
Compared to the kcat/KM value of 1.4×107 s−1M−1 for CYPA (24), CYPJ has a kcat/KM of 9.5×104 s−1M−1, which is 147-fold lower. This could be due to the difference in the molecular structure between CYPA and CYPJ. Structural difference results in the varied PPIase activity among the cyclophilin family, e.g. there is a 432-fold difference between the PPIase activity of CYP6 and CYP10 in C. elegans (25). Similarly, the IC50 for CsA against CYPJ was 12 μM compared to 19 nM for CYPA, that could be explained by the difference in CsA-CYP binding site. Our CD spectroscopy revealed resemblance in the secondary structure of CYPA and CYPJ, that was in accordance with the crystal structure of CYPJ (18).
The biological function of CYPJ (or PPIL3b) remains largely a mystery. PPIL3 mRNA was ubiquitously transcribed in adult human tissues, poorly expressed in human brain tissues and overexpressed in human glioma tissues (17, 26). PPIL3B was reported to be down-regulated in anandamide-induced apoptosis of human neuroblastoma SH-SY5Y cells (27). PPIL3 was also discovered as a direct binding partner of apoptin, which held apoptin in the cytoplasm of tumour cells, preventing the migration of apoptin into cell nucleus and killing of the tumor cell (28). Our data identified that CYPJ promoted the transcription of cis-response elements of several pathways related to cell growth, proliferation, and apoptosis (Figure 5). Our preliminary data also showed up-regulation of CYPJ expression in human hepatocellular carcinoma (Chen J, unpublished data). Overall, these findings suggested a strong involvement of CYPJ in carcinogenesis.
Conclusion
CYPJ structurally resembles CYPA. It has PPIase activity that is sensitive to inhibition by CsA and might play a role in regulating cell growth, proliferation, and apoptosis. This study adds to our current knowledge of cyclophilin family of proteins and paves the way for future research on the biological function of CYPJ.
Acknowledgements
This study was funded by National Natural Science Foundation of China (No. 30801338 and No. 81071758); Shandong Province Young and Middle-aged Scientists Research Award of China (No. 2008BSA02012 and No. BS2009SW052); Yantai Science and Technology Program (No. 2009155-3 and No. 2012085).
Footnotes
↵* These Authors contributed equally to the study.
- Received January 18, 2016.
- Revision received February 19, 2016.
- Accepted February 22, 2016.
- Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved